Resistance to apoptotic cell death1 owing to overexpression of anti-apoptotic Bcl-2 family proteins including Bcl-2, Bcl-xL or Mcl-1 is considered an interesting druggable target for the treatment of hematological malignancies including acute myeloid leukemia. Here, BCL2L1 is linked to acute myeloid leukemia.